Murray et al. [33] very recently demonstrated that BTK activity was enhanced in bortezomib-resistant MM, and that co-treatment of MM cells with ibrutinib or a p65-targeted lentiviral construct and bortezomib can partly restore bortezomib sensitivity, highlighting the crucial role of NF-kB activity in bortezomib-resistant MM. Here, BTK is linked to Miyoshi myopathy.